Models for financing the regulation of pharmaceutical promotion

Globalization and Health

Volumn 8, Issue , 2012, Pages

  Lexchin, Joel ^a,b,c  

^a YORK UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Financing; Medications; Principles; Promotion; Regulation

Indexed keywords

FINANCIAL SERVICES; HEALTH IMPACT; HEALTH MONITORING; HEALTH POLICY; PHARMACEUTICAL INDUSTRY; STANDARD (REGULATION);

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG PROMOTION; FINANCIAL MANAGEMENT; GOVERNMENT; PRIORITY JOURNAL; SOCIAL INSURANCE; TAX; WORLD HEALTH ORGANIZATION; ADVERTIZING; ECONOMICS; INAPPROPRIATE PRESCRIBING; LAW; LEGAL ASPECT; STANDARD; THEORETICAL MODEL;

ADVERTISING AS TOPIC; DRUG COSTS; DRUG INDUSTRY; FINANCING, GOVERNMENT; INAPPROPRIATE PRESCRIBING; LEGISLATION AS TOPIC; MODELS, THEORETICAL;

EID: 84863578850     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-8-24     Document Type: Article

References (27)

1. Centro Studi Farmindustria Indicatori farmaceutici 1998, Rome, Farmindustria, Centro Studi Farmindustria.
2. Gagnon M-A, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008, 5:e1. 10.1371/journal.pmed.0050001, 2174966, 18177202.
3. Boltri JM, Gordon ER, Vogel RL. Effect of antihypertensive samples on physician prescribing patterns. Fam Med 2002, 34:729-731.
4. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med 2010, 7:e1000352. 10.1371/journal.pmed.1000352, 2957394, 20976098.
5. Wall LL, Brown D. The high cost of free lunch. Obstet Gynecol 2007, 110:169-173. 10.1097/01.AOG.0000268800.46677.14, 17601912.
6. Othman N, Vitry AI, Roughead EE. Quality of pharmaceutical advertisements in medical journals: a systematic review. PLoS One 2007, 4:e6350.
7. Findlay S. Prescription drugs and mass media advertising 2000, National Institute for Health Care Management Research and Educational Foundation, Washington D.C..
8. Mintzes B. What are the public health implications? Direct-to-consumer advertising of prescription drugs in Canada 2006, Toronto: Health Council of Canada.
9. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005, 293:1995-2002. 10.1001/jama.293.16.1995, 3155410, 15855433.
10. Evans D. Big Pharma's crime spree 2009, 72-86. Bloomberg Markets.
11. Spielmans GI. The promotion of olanzapine in primary care: an examination of internal industry documents. Soc Sci Med 2009, 69:14-20. 10.1016/j.socscimed.2009.05.001, 19481322.
12. Rochon PA, Normand S-L, Gomes T, Gill SS, Anderson GM, Melo M, Skykora K, Lipscombe L, Bell CM, Gurwitz JH. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008, 168:1090-1096. 10.1001/archinte.168.10.1090, 18504337.
13. Landefeld CS, Steinman MA. The Neurontin legacy - marketing through misinformation and manipulation. N Engl J Med 2009, 360:103-106. 10.1056/NEJMp0808659, 19129523.
14. Government Accountability Office Prescription drugs: improvements needed in FDA's oversight of direct-to-consumer advertising 2006, Washington D.C, Government Accountability Office.
15. Government Accountability Office Prescription drugs: trends in FDA's oversight of direct-to-consumer advertising 2008, Washington D.C, Government Accountability Office.
16. Kiester M DDMAC submissions 2011, Drug Information Association Inc., http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/UCM246563.pdf, Kiester M.
17. Thaul S. Direct-to-consumer advertising of prescription drugs 2009, Congressional Research Service, R40590.
18. Government Accounting Office Prescription drugs: FDA's oversight of the promotion of drugs for off-label uses 2008, Washington D.C., Government Accounting Office.
19. PMCPA Prescription Medicines Code of Practice Authority: Annual Report 2010 2011, London, PMCPA.
20. Lexchin J, Kawachi I. Voluntary codes of pharmaceutical marketing: controlling promotion or licensing deception. Contested ground: public purpose and private interest in the regulation of prescription drugs 1996, 221-235. New York, Oxford University Press, Davis P.
21. Ziganshina L, Lexchin J. Regulation of pharmaceutical promotion: why does regulation matter. Understanding and responding to pharmaceutical promotion: a practical guide 2009, 123-144. Geneva and Amsterdam, World Health Organization/Health Action International, Mintzes B, Mangin D, Hayes L.
22. Health Action International http://www.haiweb.org/, Health Action International.
23. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med 2008, 358:1354-1361. 10.1056/NEJMsa0706341, 18367738.
24. Health Products and Food Branch Cost recovery framework: official notice of fee proposal for human drugs and medical devices 2007, Health Canada, Health Products and Food Branch.
25. PAAB Code of Advertising Acceptance 2009, Pickering, Pharmaceutical Advertising Advisory Board, PAAB.
26. Italian Medicines Agency (AIFA) Research & Development Working Group Feasiblity and challenges of independent research on drugs: the Italian Medicines Agency (AIFA) experience. Eur J Clin Invest 2010, 40:69-86. Italian Medicines Agency (AIFA) Research & Development Working Group.
27. Ayres I, Braithwaite J. Responsive regulation. Transcending the deregulation debate 1992, New York, Oxford University Press.